Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026
Halozyme Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.20327 EPS, expectations were $2.15.
Operator: Good afternoon. My name is Alexandra, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme’s Fourth Quarter and Full Year 2025 Financial and Operating Results Conference Call. [Operator Instructions] Please note this event...
